Comparison of platelet count reduction in patients with essential thrombocythaemia treated with hydroxyurea and thromboreductin. Single centre experience
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2019, Vol 3, Issue 8
Abstract
Essential thrombocythemia is one of the Ph-negative myeloproliferative neoplasms treated with hydroxyurea. An alternative strategy may be a therapy with thromboreductin. The aim of the study was to compare the effectiveness of hydroxyurea and thromboreductin treatment, defined by a decrease in the platelet count. The study group consisted of 154 patients with essential thrombocythemia diagnosed and treated at the Outpatient Clinic of Hematology in Krakow, Poland between 1995 and 2016. Patients were included in the study at the start of cytoreductive treatment. 102 patients was treated with hydroxyurea and 52 patients treated with thromboreducin. We set the limit values for the number of platelets on levels : <800 x 10 9 /L, <600 x 10 9 /L, <450 x 10 9 /L and <350 x 10 9 /L. Afterwards, the analysis of the time required to achieve each point was performed. A comparison of hydroxyurea and thromboreductin groups showed that the number of platelets at the beginning of therapy was significantly lower in patients treated with hydroxyurea. Platelets value in the last control was significantly lower in patients treated with thromboreductin than hydroxyurea. The change in total platelet count over the time was significantly higher in the thromboreductin group. Patients treated with thromboreductin had a faster platelets reduction lower than 450 x10 9 /L. Tromboreductin is effective in reducing the number of platelets in patients with resistant essential thrombocythemia or intolerant of hydroxyurea regardless of age. JRCD 2018; 3 (8): 266–270
Authors and Affiliations
Anna Prochwicz, Szymon Fornagiel, Katarzyna Krawczyk, Dorota Krochmalczyk
Keywords
Related Articles
- EP ID EP494146
- DOI 10.2041/jrcd.vol3no8.362
- Views 84
- Downloads 0
Cardiopulmonary exercise tests in rare cardiovascular heart diseases
Cardiopulmonary exercise testing (CPET) is commonly used in clinica practice for both functional and diagnostic assessments of patients with cardiovascular and pulmonary disease. It provides assessment of the integrative...
Pulmonary arterial hypertension in a patient with unilateral pulmonary artery absence (RCD code: II-2A.1)
Pulmonary artery absence is a rare congenital defect, occurring in 1 out of 100 000 individuals. In its isolated unilateral form only one in three cases concerns the left artery. The first symptoms usually appear in youn...
Cardiac Tumours and Malignancy Diseases
n/a
Cardiac sarcoidosis – management and prognosis (RCD code: III‑3A.3)
Sarcoidosis is a systemic, granulomatous disease of unknown etiology. Cardiac involvement in the course of sarcoidosis occurs in 5% of patients. However, about 25% of patient with systemic/pulmonary sarcoidosis might pre...
Large mediastinal teratoma causing recurrent pericarditis (RCD code: VI)
The mediastinal tumors are rare but potentially fatal diseases. Teratomas are derived from multipotent germ-line cells. In majority of cases mediastinal tumours are incidentally detected on chest X ray. We present 19-yea...